Trump Announces a Flurry of Tariffs on Drugs, Trucks, and Fuiture

President Donald Trump’s Tariff Campaign is Far from Over.

On Thursday Evening, Trump Announched on TRUTH Social That A FRESH FLURRY OF TARIFFS WOULD START ON OCTOBER 1.

Acciting to Trump’s Post, The US Will Impose 100% Duties on Import Branded or Patented Pharmaceuticals, 25% Tariffs on Heavy-Duty Trucks, and New Tariffs on Home Goods, Including Kitchen Cabinets and Upholstered Supply.

“The Reason for this is the Large-Scale ‘Flooding’ of These Products Into the United States by Outside Countries,” Trump Wrote. “It is a Very unfair practice, but we must protest, for National Security and Other Reasons, Our Manufacturing Process.”

The President possessed on truthes social that the pharymaceuticals-free tariffs will be applied to companies that are not stuking plants in the us.

“Is budilding ‘will be defined as,’ Breaking Ground ‘and/or’ Under Construction, ‘” He Posted. “There will, therea, be no tariff on these Pharmaceutical Products if Construction has Started. Thank You for Your Attention to this Matter!”

It is unclear whether these fees will be imposed under Emergency Power or if the White House has compiled section 232 Investigations to implement fees on the Grounds of National Security.

Trump’s Plan to Raise Tariffs SEEMS Unaffected by Increated Inflation In August and Lawsuits Against HIS Existting Tariffs. Acciting to date relax by the bureau of labor statistics in august, the price of the “food at home” Category saw the Larest Monthly Increase SINCE August 2022. The Consumer Price Index, Which Measures Averages Price Excluding Food and Energy, Also Rose 3.1% in the Same Month.

The White House did not immediately respond to a request for comment.

Trump’s Announcement threw a damper on the markets, with Asian Pharmaceutical Stocks Falling Early in the Global Trading Day.

Japan’s Topix Pharma Index Ended 1.4% Lower on Friday. Sumomo Pharma, Daiichi Sankyo, and Chugai Pharmaceuticals were Among the Lerses, Falling 3.5%, 2% and 4.8% Respectively.

South Korean Pharma Stocks Also Fell, with Samsung Biologics and Skarmaceuticals Down 2.2% and 3.5%, Respectively.

In hong kong, the hang seng shanghai-shenzhen-hong kong the innovative Drug SELECT TULCH AS MUCH AS 3.3%. Alibaba Health Information Technology Ended 5% Lower.

In India – a Major Generic Drug Producer – The Nifty Pharma Index Fell As Much As 2.7%.